ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

gemigliptin

Also written as “Gemigliptin”, “Gemigliptin 50mg” and “gemigliptin/metformin HCl extended release”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Renal Insufficiency, led by 2 companies.

Drug pageGemigliptin: every studyAll 36 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since May 24, 201330 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
LG Chem290 open or runningphase 4since May 24, 2013Oct 21, 2009none ahead
Stendhal Americasits history only10 open or runningphase 1since Sep 13, 2017Sep 13, 2017none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of LG Chem only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 13 studies since Oct 21, 2009.

  1. Nov 15, 2013Phase 3 study in Diabetes Mellitus, Type 2NCT01990469 · 219 enrolled
  2. Feb 5, 2014Phase 1 study in HealthyNCT02056600 · 24 enrolled · Korea, Republic of
  3. Mar 4, 20142 phase 3 studies in Diabetes Mellitus, Type 2NCT02126358, NCT02089126
  4. Dec 22, 20152 phase 1 studies in HealthyNCT02670070, NCT02670018
  5. Jun 23, 2016Phase 3 study in Diabetes Mellitus, Type 2NCT02831361 · 290 enrolled
  6. Jun 26, 2017Phase 4 study in Diabetes Mellitus, Type 2NCT03202563 · 71 enrolled · Korea, Republic of
  7. Nov 9, 2017Phase 1 study in Healthy Male VolunteersNCT03355014 · 70 enrolled · Korea, Republic of
  8. May 24, 2018Phase 1 study in Diabetes Mellitus, Type 2NCT03565458 · 48 enrolled · Korea, Republic of
  9. Feb 13, 2019Phase 3 study in Diabetes Mellitus, Type 2NCT03842267 · 315 enrolled · Korea, Republic of
  10. Mar 4, 2019Phase 1 study in Diabetes Mellitus, Type 2NCT03864432 · 48 enrolled · China
  11. Aug 21, 2019Phase 1 study in Type2 DiabetesNCT04070794 · 24 enrolled
  12. Feb 2, 2020Phase 3 study in Diabetes Mellitus, Type 2NCT04255238 · 468 enrolled
  13. Jul 29, 2020Phase 1 study in T2DMNCT04544319 · 44 enrolled
  14. Jan 23, 2026Phase 1 study in Healthy VolunteersNCT07399470 · 58 enrolled · South Korea

TargetBeta

DPP4 →read by rule
“An orally bioavailable inhibitor of the serine protease dipeptidyl peptidase 4 (DPP-4), with hypoglycemic and potential renoprotective activities”NCIt, by rule
“Dipeptidyl peptidase IV inhibitor”ChEMBL 37, by rule

Other programs on DPP4

ProgramCompanyFurthest phaseStudies
sitagliptinruleMerckphase 4123
LinagliptinruleBoehringer Ingelheimphase 496
anagliptinruleJW Pharmaceuticalphase 46
Empagliflozin/LinagliptinruleHumanis Saglık Anonim Sirketiphase 12
cofrogliptinruleHaisco Pharmaceutical Groupno phase1

Studies

All 29 LG Chem leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07399470Healthy Volunteers · South Korea1CompletedFeb 6, 202658
NCT04544319T2DM1UNKNOWNMar 202144
NCT04255238Diabetes Mellitus, Type 23UNKNOWNMay 30, 2022468
NCT04070794Type2 Diabetes1UNKNOWNNov 30, 201924
NCT03864432Diabetes Mellitus, Type 2 · China1CompletedOct 3, 201948
NCT03842267Diabetes Mellitus, Type 2 · Korea, Republic of3CompletedMay 20, 2021315
NCT03565458Diabetes Mellitus, Type 2 · Korea, Republic of1UNKNOWNAug 20, 201848
NCT03355014Healthy Male Volunteers · Korea, Republic of1CompletedJan 12, 201870
NCT03202563Diabetes Mellitus, Type 2 · Korea, Republic of4CompletedJul 13, 201871
NCT02831361Diabetes Mellitus, Type 23CompletedFeb 8, 2018290
NCT02670070Healthy · Korea, Republic of1UNKNOWNApr 201637
NCT02670018Healthy · Korea, Republic of1UNKNOWNDec 201525
NCT02089126Diabetes Mellitus, Type 2 · Korea, Republic of3UNKNOWNSep 2016230
NCT02126358Diabetes Mellitus, Type 2 · Korea, Republic of3CompletedMar 2016290
NCT02056600Healthy · Korea, Republic of1CompletedApr 201424
NCT01990469Diabetes Mellitus, Type 23CompletedApr 2015219
NCT02004587Hepatic Impairment · Germany1CompletedMay 201428
NCT01968044Renal Insufficiency · Korea, Republic of3CompletedOct 2015132
NCT01890629Diabetes Mellitus, Type 2 · Korea, Republic of4CompletedAug 201469
NCT01825850Healthy · Korea, Republic of1CompletedSep 201330
NCT01787396Diabetes Mellitus, Type 2 · Korea, Republic of3CompletedMar 2015433
NCT01768455Healthy · Korea, Republic of1CompletedApr 201327
NCT01662674Healthy · Korea, Republic of1CompletedNov 201227
NCT01603238Healthy · Korea, Republic of1CompletedMay 20116
NCT01602003Diabetes Mellitus, Type 2 · Korea, Republic of3CompletedJun 2011425
NCT01601990Diabetes Mellitus, Type 2 · Korea, Republic of3CompletedMar 2011189
NCT01595880Healthy · Korea, Republic of1CompletedJan 201529
NCT01426399Healthy · Korea, Republic of1CompletedNov 201130
NCT01001013Healthy · Korea, Republic of1CompletedJun 200924

How it is read

Names in the registry

  • “Gemigliptin”, 7 entries
  • “Gemigliptin 50mg”, 5 entries
  • “gemigliptin/metformin HCl extended release”, 3 entries
  • “gemigliptin and metformin HCl extended release”, 3 entries
  • “LC15-0444 50mg qd”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.